



AXIA BEST MANAGED COMPANY AWARD GOES TO CHEPLAPHARM

Düsseldorf/Greifswald (DE), May 10, 2019 – CHEPLAPHARM Arzneimittel GmbH received the "Axia Best Managed Companies Award" (Axia BMC Award) yesterday. With the award and seal of quality, the audit and consulting firm Deloitte, WirtschaftsWoche and BDI are honouring best managed medium-sized companies.

We are absolutely delighted about this award," summarized CHEPLAPHARM's CEO Sebastian F. Braun at the award ceremony, "because now we are ranked amongst companies and award winners as Sixt, Alfred Kärcher, Sennheiser, Vorwerk, UVEX or Hansgrohe, just to name a few. Furthermore, what we are proud of and what is now recognized is that in the last five years we achieved to become one of the top 5 medium-sized non-listed German pharmaceutical companies.



The Axia Best Managed Companies (BMC) program is a competition conducted by Deloitte, WirtschaftsWoche and BDI in Germany for successful medium-sized companies with the vision of building a national and global ecosystem of excellently managed mid-sized companies. One of BMC's unique characteristic is its international orientation:

Launched by Deloitte in Canada in the 1990s, BMC is now present in thirteen countries and will be successfully launched in 2020 in at least twenty countries.

The winners of the Axia BMC Award were identified in a multi-stage, complex procedure. In the first step, companies had to complete an online questionnaire. Basic company data were queried and the positioning in the four core content areas of the award was examined: Strategy, Productivity & Innovation, Culture & Commitment, Governance & Finance. On the basis of the application documents, evaluations and personal interviews, the expert council of the Axia Best Managed Companies Award defined the shortlist. Subsequently, the winners were selected by a jury consisting of renowned representatives from business, science and media. Speaker of the jury is Dr. med. Hans-Toni Junius, Managing Partner and Chairman of the Management of C.D. Wälzholz GmbH & Co. KG and Presidential Member of the BDI.

With the Axia Best Managed Companies Award we aim to build an ecosystem and network for excellently managed mid-sized businesses - in Germany and around the world. We congratulate and look forward to welcoming CHEPLAPHARM into this exclusive circle of successful companies", added Markus Seiz, Axia BMC Program Manager.

About CHEPLAPHARM

CHEPLAPHARM is a pharmaceutical company headquartered in Greifswald, Germany, offering branded and niche products in more than 120 countries worldwide. The family-owned company specializes in selected active substances and indications and focuses on an international buy-and-build strategy.

Working closely with its business partners, CHEPLAPHARM achieves sustainable annual growth rates.

CHEPLAPHARM has been one of the fastest-growing pharmaceutical companies in Europe for years with projected annual sales of 500 million euros in 2019.

Please refer to www.cheplapharm.com for additional information.

Further information about Deloitte can be found at www.deloitte.com/about and about WirtschaftsWoche at <https://www.wiwo.de/>

Press Office:

CHEPLAPHARM Arzneimittel GmbH | Ziegelhof 24 | 17489 Greifswald | presse@cheplapharm.com